Floatz logo

Vancomycin

Diffuse Large B Cell Lymphoma (DLBCL)

Abramson Cancer Center at Penn MedicineSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Diffuse Large B Cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3B
VINBLASTINE
Fondazione Italiana Linfomi - ETS
Phase 3B
Polatuzumab
Beijing Tongren Hospital
Phase 2B
Obutinib
Ruijin Hospital
Phase 2B
Rondecabtagene Autoleucel
Lyell Immunopharma, Inc.
Phase 3B

View all 20 →

Same molecule, other indications

Vancomycin is also rated in:

primary sclerosing cholangitisDormant
BB
Indicative ·
71 / 100
View asset →
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →
Febrile Neutropenia (FN)Dormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →